Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:PRR5-ARHGAP8

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: PRR5-ARHGAP8
	FusionPDB ID: 69171
	FusionGDB2.0 ID: 69171
		Hgene	Tgene
	Gene symbol	PRR5	ARHGAP8
	Gene ID	55615	23779
	Gene name	proline rich 5	Rho GTPase activating protein 8
	Synonyms	FLJ20185k\|PP610\|PROTOR-1\|PROTOR1	BPGAP1\|PP610
	Cytomap	22q13.31	22q13.31
	Type of gene	protein-coding	protein-coding
	Description	proline-rich protein 5Rho GTPase activating protein 8proline rich 5 (renal)protein observed with Rictor-1	rho GTPase-activating protein 8BCH domain-containing Cdc42GAP-like proteinBNIP-2 and Cdc42GAP homology domain-containing, proline-rich and Cdc42GAP-like protein subtype-1rho-type GTPase-activating protein 8
	Modification date	20200313	20200313
	UniProtAcc	.	P85298 Main function of 5'-partner protein: FUNCTION: GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state. {ECO:0000250}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000477331, ENST00000006251, ENST00000336985, ENST00000403581,	ENST00000336963, ENST00000356099, ENST00000389773, ENST00000389774, ENST00000517296, ENST00000469872,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	4 X 6 X 3=72	6 X 9 X 5=270
	# samples	5	7
	** MAII score	log2(5/72*10)=-0.526068811667588 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(7/270*10)=-1.94753258010586 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: PRR5 [Title/Abstract] AND ARHGAP8 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: PRR5 [Title/Abstract] AND ARHGAP8 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ARHGAP8(45182486)-PRR5(45098372), # samples:1 PRR5(45110550)-ARHGAP8(45241148), # samples:1 PRR5(45122513)-ARHGAP8(45241148), # samples:1 PRR5(NA)-ARHGAP8(NA), # samples:1 PRR5(45122514)-ARHGAP8(45182337), # samples:1
Anticipated loss of major functional domain due to fusion event.	PRR5-ARHGAP8 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PRR5-ARHGAP8 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PRR5-ARHGAP8 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PRR5-ARHGAP8 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PRR5-ARHGAP8 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. PRR5-ARHGAP8 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	ARHGAP8	GO:0070374	positive regulation of ERK1 and ERK2 cascade	20179103

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr22:45182486/chr22:45098372)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across PRR5 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ARHGAP8 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000006251	PRR5	chr22	45110550	+	ENST00000517296	ARHGAP8	chr22	45241148	+	1199	382	41	1087	348
ENST00000006251	PRR5	chr22	45110550	+	ENST00000389773	ARHGAP8	chr22	45241148	+	1277	382	41	1087	348
ENST00000006251	PRR5	chr22	45110550	+	ENST00000389774	ARHGAP8	chr22	45241148	+	1277	382	41	1087	348
ENST00000006251	PRR5	chr22	45110550	+	ENST00000336963	ARHGAP8	chr22	45241148	+	1174	382	41	703	220
ENST00000006251	PRR5	chr22	45110550	+	ENST00000356099	ARHGAP8	chr22	45241148	+	1277	382	41	1087	348
ENST00000403581	PRR5	chr22	45110550	+	ENST00000517296	ARHGAP8	chr22	45241148	+	1710	893	588	1598	336
ENST00000403581	PRR5	chr22	45110550	+	ENST00000389773	ARHGAP8	chr22	45241148	+	1788	893	588	1598	336
ENST00000403581	PRR5	chr22	45110550	+	ENST00000389774	ARHGAP8	chr22	45241148	+	1788	893	588	1598	336
ENST00000403581	PRR5	chr22	45110550	+	ENST00000336963	ARHGAP8	chr22	45241148	+	1685	893	1295	627	222
ENST00000403581	PRR5	chr22	45110550	+	ENST00000356099	ARHGAP8	chr22	45241148	+	1788	893	588	1598	336
ENST00000336985	PRR5	chr22	45110550	+	ENST00000517296	ARHGAP8	chr22	45241148	+	1309	492	277	1197	306
ENST00000336985	PRR5	chr22	45110550	+	ENST00000389773	ARHGAP8	chr22	45241148	+	1387	492	277	1197	306
ENST00000336985	PRR5	chr22	45110550	+	ENST00000389774	ARHGAP8	chr22	45241148	+	1387	492	277	1197	306
ENST00000336985	PRR5	chr22	45110550	+	ENST00000336963	ARHGAP8	chr22	45241148	+	1284	492	277	813	178
ENST00000336985	PRR5	chr22	45110550	+	ENST00000356099	ARHGAP8	chr22	45241148	+	1387	492	277	1197	306

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000006251	ENST00000517296	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.09376334	0.9062367
ENST00000006251	ENST00000389773	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.09012462	0.9098754
ENST00000006251	ENST00000389774	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.09012462	0.9098754
ENST00000006251	ENST00000336963	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.025268128	0.9747319
ENST00000006251	ENST00000356099	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.09012462	0.9098754
ENST00000403581	ENST00000517296	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.068179004	0.93182105
ENST00000403581	ENST00000389773	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.06208617	0.9379139
ENST00000403581	ENST00000389774	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.06208617	0.9379139
ENST00000403581	ENST00000336963	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.027141003	0.97285897
ENST00000403581	ENST00000356099	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.06208617	0.9379139
ENST00000336985	ENST00000517296	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.03638481	0.96361524
ENST00000336985	ENST00000389773	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.03353861	0.96646136
ENST00000336985	ENST00000389774	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.03353861	0.96646136
ENST00000336985	ENST00000336963	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.015644744	0.98435533
ENST00000336985	ENST00000356099	PRR5	chr22	45110550	+	ARHGAP8	chr22	45241148	+	0.03353861	0.96646136

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PRR5-ARHGAP8

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene

Hchr

Hbp

Tgene

Tchr

Tbp

Length(fusion protein)

BP in fusion protein

Peptide

Top

Potential FusionNeoAntigen Information of PRR5-ARHGAP8 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA I

FusionNeoAntigen peptide

Binding score

Immunogenic score

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Potential FusionNeoAntigen Information of PRR5-ARHGAP8 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of PRR5-ARHGAP8

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PRR5-ARHGAP8

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele

PDB ID

File name

BPseq

Docking score

Glide score

Top

Vaccine Design for the FusionNeoAntigens of PRR5-ARHGAP8

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide sequence

FusionNeoAntigen RNA sequence

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of PRR5-ARHGAP8

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type

Fusion gene

Hchr

Hbp

Henst

Tchr

Tbp

Tenst

Sample

Top

Potential target of CAR-T therapy development for PRR5-ARHGAP8

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to PRR5-ARHGAP8

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to PRR5-ARHGAP8

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)